BetaGlue® Therapeutics is a clinical-stage precision oncology company developing localized radiotherapeutic platforms for solid tumors. By combining biotechnology, nuclear science and interventional oncology, we deliver radiation directly where it matters most — inside the tumor.
YntraDose® is a first-in-class localized radiotherapeutic platform: a one-time, image-guided intratumoral injection of Yttrium-90 microspheres, designed to provide durable local control of the primary tumor.
Designed to complement next-generation systemic therapies — including the KRAS era — YntraDose is being developed to address the local-control gap where current approaches fall short. YntraDose is investigational; its safety and performance are being evaluated in clinical development.
Pancreatic cancer is entering a period of rapid change. Three developments are reshaping how the disease will be treated — and BetaGlue sits at their intersection.
Molecular characterisation is turning a single disease into a set of distinct, separately treatable subtypes — and expectations of what treatment should achieve are rising with it.
A new generation of targeted agents is entering clinical development against one of the defining drivers of pancreatic cancer.
As systemic disease is controlled for longer, durable control of the primary tumor is increasingly recognised as a determinant of clinical outcome.
BetaGlue is building the local control platform at the point where these three trends meet.
A one-time, image-guided intratumoral administration that delivers durable local control — without interrupting the systemic backbone.
YntraDose® has been evaluated in two first-in-human studies, establishing an early clinical foundation. It now supports development in locally advanced pancreatic cancer (LA-PDAC), in combination with next-generation systemic therapies.
YntraDose® is being developed first in locally advanced pancreatic cancer — with the potential of a localized radiotherapeutic platform across solid tumors.
| Program | Pre-clinical | Clinical | |
|---|---|---|---|
| Phase 1 | Phase 2/3 | ||
| PancreasLead program | |||
Four steps, from preparation to targeted delivery.
For many solid tumors — beginning with locally advanced pancreatic cancer — controlling the primary tumor locally remains a major challenge, even as systemic therapies advance.
BetaGlue is building a localized radiotherapeutic platform designed to deliver durable local control precisely at the tumor — to complement next-generation systemic therapies, not replace them.
Our purpose: make precise, image-guided local control a practical part of combination cancer care — and, over time, extend it across solid tumors.
The impact of the clinical benefits for patients thanks to this new personalised radiotherapeutic treatment option are potentially broad.
English translation of an article originally published in Italian by Fondazione Policlinico Universitario A. Gemelli IRCCS on 1 October 2026. Rome, October 1st 2026 – For the first time in…
Read moreMilan, August 14th 2026 – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumors, called YntraDose®,…
Read moreBetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose® Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) Milan, December 15th, 2025 (GlobeNewswire) – BetaGlue® Therapeutics (“BetaGlue” or the…
Read more
